Zidovudine in the management of primary HIV-1 infection

B Tindall, H Gaines, A Imrie, M A Von Sydow, L Evans, O. Strannegard, M L Tsang, S Lindback, D A Cooper

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Eleven subjects who presented with a clinical illness characteristic of primary HIV-1 infection were treated with 1 g zidovudine daily for a median period of 56 days (range, 28-111 days). Primary HIV-1 infection was confirmed in each subject by seroconversion and virus isolation. The acute phase of the illness resolved a median of 4 days (range, 3-14 days) from commencement of zidovudine. Six subjects reported symptoms that may have been side-effects of zidovudine, the most common being nausea in four subjects and headache in two. Treatment was discontinued in one subject who had persistent headache and nausea. Haemoglobin, haematocrit and erythrocyte counts decreased and mean corpuscular volume increased significantly during the treatment. None of the subjects developed anaemia and none required dose modification or blood transfusion as a result of haematological side-effects. There were no significant differences in the granulocyte count or the lymphocyte count during any week of treatment when compared with baseline levels. There were no significant differences in T-cell subset numbers of the subjects during treatment compared with a group of historical controls. HIV-1 was isolated from several subjects during and after termination of zidovudine treatment. The results of this investigation indicate that zidovudine is a safe drug to administer to people with primary HIV-1 infection. There was no clear evidence, however, of any clinical benefit in terms of resolution of the acute illness and no indication that the treatment would prevent development of persistent infection.(ABSTRACT TRUNCATED AT 250 WORDS)

Original languageEnglish
Pages (from-to)477-84
Number of pages8
JournalAIDS
Volume5
Issue number5
Publication statusPublished - May 1991

Fingerprint

Zidovudine
HIV Infections
HIV-1
Nausea
Headache
Therapeutics
Erythrocyte Count
Erythrocyte Indices
Lymphocyte Count
T-Lymphocyte Subsets
Hematocrit
Granulocytes
Blood Transfusion
Anemia
Hemoglobins
Cell Count
Viruses
Control Groups
Infection
Pharmaceutical Preparations

Cite this

Tindall, B., Gaines, H., Imrie, A., Von Sydow, M. A., Evans, L., Strannegard, O., ... Cooper, D. A. (1991). Zidovudine in the management of primary HIV-1 infection. AIDS, 5(5), 477-84.
Tindall, B ; Gaines, H ; Imrie, A ; Von Sydow, M A ; Evans, L ; Strannegard, O. ; Tsang, M L ; Lindback, S ; Cooper, D A. / Zidovudine in the management of primary HIV-1 infection. In: AIDS. 1991 ; Vol. 5, No. 5. pp. 477-84.
@article{e431294a90d44b60bde8739e50d5d165,
title = "Zidovudine in the management of primary HIV-1 infection",
abstract = "Eleven subjects who presented with a clinical illness characteristic of primary HIV-1 infection were treated with 1 g zidovudine daily for a median period of 56 days (range, 28-111 days). Primary HIV-1 infection was confirmed in each subject by seroconversion and virus isolation. The acute phase of the illness resolved a median of 4 days (range, 3-14 days) from commencement of zidovudine. Six subjects reported symptoms that may have been side-effects of zidovudine, the most common being nausea in four subjects and headache in two. Treatment was discontinued in one subject who had persistent headache and nausea. Haemoglobin, haematocrit and erythrocyte counts decreased and mean corpuscular volume increased significantly during the treatment. None of the subjects developed anaemia and none required dose modification or blood transfusion as a result of haematological side-effects. There were no significant differences in the granulocyte count or the lymphocyte count during any week of treatment when compared with baseline levels. There were no significant differences in T-cell subset numbers of the subjects during treatment compared with a group of historical controls. HIV-1 was isolated from several subjects during and after termination of zidovudine treatment. The results of this investigation indicate that zidovudine is a safe drug to administer to people with primary HIV-1 infection. There was no clear evidence, however, of any clinical benefit in terms of resolution of the acute illness and no indication that the treatment would prevent development of persistent infection.(ABSTRACT TRUNCATED AT 250 WORDS)",
keywords = "Acquired Immunodeficiency Syndrome/drug therapy, Blood Cell Count/drug effects, Drug Administration Schedule, Gene Products, gag/blood, HIV Antigens/blood, HIV Core Protein p24, HIV Infections/drug therapy, HIV Seropositivity, HIV-1/isolation & purification, Humans, Male, T-Lymphocyte Subsets/drug effects, Viral Core Proteins/blood, Zidovudine/administration & dosage",
author = "B Tindall and H Gaines and A Imrie and {Von Sydow}, {M A} and L Evans and O. Strannegard and Tsang, {M L} and S Lindback and Cooper, {D A}",
year = "1991",
month = "5",
language = "English",
volume = "5",
pages = "477--84",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams & Wilkins",
number = "5",

}

Tindall, B, Gaines, H, Imrie, A, Von Sydow, MA, Evans, L, Strannegard, O, Tsang, ML, Lindback, S & Cooper, DA 1991, 'Zidovudine in the management of primary HIV-1 infection' AIDS, vol. 5, no. 5, pp. 477-84.

Zidovudine in the management of primary HIV-1 infection. / Tindall, B; Gaines, H; Imrie, A; Von Sydow, M A; Evans, L; Strannegard, O.; Tsang, M L; Lindback, S; Cooper, D A.

In: AIDS, Vol. 5, No. 5, 05.1991, p. 477-84.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Zidovudine in the management of primary HIV-1 infection

AU - Tindall, B

AU - Gaines, H

AU - Imrie, A

AU - Von Sydow, M A

AU - Evans, L

AU - Strannegard, O.

AU - Tsang, M L

AU - Lindback, S

AU - Cooper, D A

PY - 1991/5

Y1 - 1991/5

N2 - Eleven subjects who presented with a clinical illness characteristic of primary HIV-1 infection were treated with 1 g zidovudine daily for a median period of 56 days (range, 28-111 days). Primary HIV-1 infection was confirmed in each subject by seroconversion and virus isolation. The acute phase of the illness resolved a median of 4 days (range, 3-14 days) from commencement of zidovudine. Six subjects reported symptoms that may have been side-effects of zidovudine, the most common being nausea in four subjects and headache in two. Treatment was discontinued in one subject who had persistent headache and nausea. Haemoglobin, haematocrit and erythrocyte counts decreased and mean corpuscular volume increased significantly during the treatment. None of the subjects developed anaemia and none required dose modification or blood transfusion as a result of haematological side-effects. There were no significant differences in the granulocyte count or the lymphocyte count during any week of treatment when compared with baseline levels. There were no significant differences in T-cell subset numbers of the subjects during treatment compared with a group of historical controls. HIV-1 was isolated from several subjects during and after termination of zidovudine treatment. The results of this investigation indicate that zidovudine is a safe drug to administer to people with primary HIV-1 infection. There was no clear evidence, however, of any clinical benefit in terms of resolution of the acute illness and no indication that the treatment would prevent development of persistent infection.(ABSTRACT TRUNCATED AT 250 WORDS)

AB - Eleven subjects who presented with a clinical illness characteristic of primary HIV-1 infection were treated with 1 g zidovudine daily for a median period of 56 days (range, 28-111 days). Primary HIV-1 infection was confirmed in each subject by seroconversion and virus isolation. The acute phase of the illness resolved a median of 4 days (range, 3-14 days) from commencement of zidovudine. Six subjects reported symptoms that may have been side-effects of zidovudine, the most common being nausea in four subjects and headache in two. Treatment was discontinued in one subject who had persistent headache and nausea. Haemoglobin, haematocrit and erythrocyte counts decreased and mean corpuscular volume increased significantly during the treatment. None of the subjects developed anaemia and none required dose modification or blood transfusion as a result of haematological side-effects. There were no significant differences in the granulocyte count or the lymphocyte count during any week of treatment when compared with baseline levels. There were no significant differences in T-cell subset numbers of the subjects during treatment compared with a group of historical controls. HIV-1 was isolated from several subjects during and after termination of zidovudine treatment. The results of this investigation indicate that zidovudine is a safe drug to administer to people with primary HIV-1 infection. There was no clear evidence, however, of any clinical benefit in terms of resolution of the acute illness and no indication that the treatment would prevent development of persistent infection.(ABSTRACT TRUNCATED AT 250 WORDS)

KW - Acquired Immunodeficiency Syndrome/drug therapy

KW - Blood Cell Count/drug effects

KW - Drug Administration Schedule

KW - Gene Products, gag/blood

KW - HIV Antigens/blood

KW - HIV Core Protein p24

KW - HIV Infections/drug therapy

KW - HIV Seropositivity

KW - HIV-1/isolation & purification

KW - Humans

KW - Male

KW - T-Lymphocyte Subsets/drug effects

KW - Viral Core Proteins/blood

KW - Zidovudine/administration & dosage

M3 - Article

VL - 5

SP - 477

EP - 484

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 5

ER -

Tindall B, Gaines H, Imrie A, Von Sydow MA, Evans L, Strannegard O et al. Zidovudine in the management of primary HIV-1 infection. AIDS. 1991 May;5(5):477-84.